ARCT

Arcturus Therapeutics Holdings Inc

10.35

Nov 06 • 3:59 PM ET +0.99 (10.58%)

10.30

Aftermarket • 7:30 PM ET -0.05 (-0.48%)

Healthcare Biotechnology USA Micro NASD

Nov 05, 7:11 PMArcturus delays planned end-of-Phase 2 FDA meeting for ARCT-2601 OTC program to after late-2027 data, pushing pivotal path back about a year

Peers: MRNA BNTX NVAX FDMT RARE RNAC KRYS EDIT VIR OCGN

| Held by: ARKG VTI IWM VXF IWN VTWO IBB SCHA VHT DWAS

Scroll to Statements

Index	RUT
Market Cap	298.31M
Enterprise Value	135.35M
Income	-87.24M
Sales	21.42M
Book/sh	5.93
Cash/sh	6.41
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	111
IPO	May 22, 2013

P/E	-
Forward P/E	-
PEG	-
P/S	13.93
P/B	1.75
P/C	1.61
P/FCF	-
EV/EBITDA	-
EV/Sales	6.32
Quick Ratio	6.68
Current Ratio	6.68
Debt/Eq	0.13
LT Debt/Eq	0.11
Option/Short	Yes / Yes

EPS (ttm)	-3.08
EPS next Y	-3.55
EPS next Q	-0.83
EPS this Y	-26.00%
EPS next Y	-17.44%
EPS next 5Y	-12.37%
EPS past 3/5Y	- 7.53%
Sales past 3/5Y	-31.15% 47.77%
EPS Y/Y TTM	-25.04%
Sales Y/Y TTM	-74.84%
EPS Q/Q	47.29%
Sales Q/Q	19.07%
Earnings	Nov 05 AMC
EPS/Sales Surpr.	62.13% 128.80%

Insider Own	8.36%
Insider Trans	0.00%
Inst Own	80.03%
Inst Trans	-3.90%
ROA	-35.06%
ROE	-44.37%
ROIC	-46.66%
Gross Margin	88.14%
Oper. Margin	-463.82%
Profit Margin	-407.24%
SMA20	-4.35%
SMA50	-20.99%
SMA200	14.18%
Trades

Shs Outstand	28.46M
Shs Float	26.41M
Short Float	20.67%
Short Ratio	5.46
Short Interest	5.46M
52W High	17.96 -42.37%
52W Low	5.50 88.18%
Volatility	13.12% 10.09%
ATR (14)	1.19
RSI (14)	45.21
Beta	2.63
Rel Volume	0.68
Avg Volume	999.29K
Volume	679,868

Perf Week	-6.16%
Perf Month	-19.58%
Perf Quarter	46.81%
Perf Half Y	12.26%
Perf YTD	68.84%
Perf Year	24.85%
Perf 3Y	-43.81%
Perf 5Y	-72.33%
Perf 10Y	-17.86%
Recom	1.31
Target Price	23.80
Prev Close	9.36
Price	10.35
Change %	10.58%

Consensus

Strong Buy

Avg. Price Target

$23.80

Implied Upside

+130.0%

Analysts15incl. previous ratings

Rating Distribution10 Buy · 3 Hold · 2 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 24, 2026	Upgrade	CCitigroup	Neutral → Buy	$20	+93.2%
Mar 18, 2026	Initiated	RB. Riley Securities	Buy	$22	+112.6%
Jan 23, 2026	Initiated	RRoth Capital	Buy	$20	+93.2%
Oct 24, 2025	Downgrade	HH.C. Wainwright	Buy → Neutral	$12	+15.9%
Oct 23, 2025	Downgrade	CCitigroup	Buy → Neutral	$12	+15.9%
Oct 22, 2025	Downgrade	GGuggenheim	Buy → Neutral
Sep 04, 2025	Resumed	HH.C. Wainwright	Buy	$60	+479.7%
May 28, 2025	Initiated	BScotiabank	Sector Outperform	$32	+209.2%
Jan 28, 2025	Initiated	BBTIG Research	Buy	$41	+296.1%
Aug 12, 2024	Initiated	LLeerink Partners	Outperform	$70	+576.3%
Dec 13, 2023	Initiated	CCanaccord Genuity	Buy	$90	+769.6%
Jul 24, 2023	Initiated	WWilliam Blair	Outperform	$71	+586.0%
May 11, 2023	Upgrade	HH.C. Wainwright	Neutral → Buy	$19 → $51	+392.8%
Nov 14, 2022	Resumed	WWells Fargo	Overweight	$35	+238.2%
Nov 10, 2022	Downgrade	RRobert W. Baird	Neutral → Underperform	$18	+73.9%
Nov 03, 2022	Upgrade	CCitigroup	Neutral → Buy	$22 → $35	+238.2%
Nov 02, 2022	Upgrade	BBarclays	Underweight → Equal Weight	$16 → $25	+141.5%
Aug 10, 2022	Downgrade	RRaymond James	Mkt Perform → Underperform
Jul 19, 2022	Resumed	CCantor Fitzgerald	Overweight	$86 → $39	+276.8%
May 11, 2022	Upgrade	RRobert W. Baird	Underperform → Neutral	$21 → $18	+73.9%

Nov-05-26 06:46PM	Arcturus Beats On A One-Time CSL Windfall, But The Real Story Is A Bigger Pipeline With Later Decision Points (Earnings Whispers) -13.89% +10.58%
03:01PM	Arcturus Therapeutics Announces Third Quarter 2026 Financial Results and Pipeline Progress (Business Wire)
Oct-28-26 06:21PM	Arcturus Heads Into Q3 With OTC Data Window Closed And A Rallied Stock Awaiting Proof (Earnings Whispers) +7.48%
Oct-26-26 04:01PM	Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026 (Business Wire) +13.32%
Sep-24-26 09:41AM	CoreWeave upgraded, Etsy downgraded: Wall Street's top analyst calls (The Fly) +6.17%
04:01PM	Loading…
Sep-23-26 04:01PM	Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0 Next-Generation mRNA Delivery Platform (Business Wire) -7.51%
Sep-18-26 09:00AM	Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform (Business Wire) -5.32%
Aug-31-26 04:01PM	Arcturus Therapeutics to Participate in Upcoming Investor Conferences (Business Wire) +9.93%
Aug-21-26 02:54PM	Can mRNA Cure Cancer? Inside the Pipeline Risks for Biotech's Biggest Players (Barrons.com) +22.38%
01:44PM	Why Moderna's mRNA Cancer Drug Hype Has Gone Too Far (Barrons.com)
Aug-06-26 04:01PM	Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress (Business Wire) +21.87%
Aug-05-26 09:43AM	Earnings To Watch: Arcturus Therapeutics Holdings Inc (ARCT) Q2 2026 -- GF Value Sees 44% Downside (GuruFocus.com)
Jul-28-26 04:01PM	Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026 (Business Wire)
Jul-20-26 04:01PM	Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference (Business Wire)
May-26-26 04:01PM	Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference (Business Wire) +6.24%
04:01PM	Loading…
May-07-26 04:01PM	Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress (Business Wire)
May-06-26 09:33AM	Arcturus Therapeutics Holdings Inc (ARCT) Q1 2026 Earnings Report Preview: What To Expect (GuruFocus.com) +8.56%
Apr-27-26 04:01PM	Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026 (Business Wire) +6.87%
Mar-05-26 09:00AM	Arcturus Therapeutics to Attend Upcoming Investor Conference (Business Wire)
Mar-04-26 12:01AM	Arcturus Therapeutics Holdings Inc (ARCT) Q4 2025 Earnings Call Highlights: Navigating Revenue ... (GuruFocus.com)
Mar-03-26 06:02PM	Arcturus Therapeutics Q4 Earnings Call Highlights (MarketBeat) -5.27%
05:10PM	Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress (Business Wire)
Mar-02-26 08:15AM	Compugen (CGEN) Beats Q4 Earnings and Revenue Estimates (Zacks)
07:20AM	What To Expect From Arcturus Therapeutics Holdings Inc (ARCT) Q4 2025 Earnings (GuruFocus.com)
Feb-26-26 01:30PM	Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Feb-17-26 04:01PM	Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026 (Business Wire)
Feb-11-26 12:52PM	Arcturus Therapeutics Spotlights Inhaled mRNA CF Phase 2b Plan, FDA Talks for OTC Program at Summit (MarketBeat)
Feb-09-26 02:14PM	Citi Lowers Price Target on Arcturus Therapeutics Holdings Inc. (ARCT) to $7, Maintains Neutral Rating (Insider Monkey)
Feb-02-26 09:54AM	Roth Capital Say Market Pricing Implies Zero Success for Arcturus Therapeutics Holdings Inc. (ARCT) Pipeline Assets (Insider Monkey)
10:06PM	Loading…
Jan-12-26 10:06PM	Arcturus Therapeutics Maps Near-Term Milestones for CF mRNA Therapy, ARCT-810 at J.P. Morgan Conference (MarketBeat) +11.06%
Jan-10-26 12:00PM	1 Under-$10 Stock Set to Surge as Much as 963% in 2026 (Barchart)
Jan-08-26 05:30PM	Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-09-25 07:58AM	Cathie Wood Dumps Tesla Again, Pours Millions Into This Tech Gaint (GuruFocus.com)
Dec-01-25 11:41AM	ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know (Zacks)
Nov-24-25 04:01PM	Arcturus Therapeutics to Attend Upcoming Investor Conference (Business Wire) +7.42%
Nov-11-25 12:03AM	Arcturus Therapeutics Holdings Inc (ARCT) Q3 2025 Earnings Call Highlights: Navigating ... (GuruFocus.com)
Nov-10-25 05:10PM	Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:07PM	Arcturus Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress (Business Wire)
Nov-07-25 07:22AM	What To Expect From Arcturus Therapeutics Holdings Inc (ARCT) Q3 2025 Earnings (GuruFocus.com) +5.19%
Nov-06-25 09:15AM	Sangamo Therapeutics (SGMO) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-04-25 04:01PM	Arcturus Therapeutics to Attend Upcoming Investor Conferences (Business Wire)
10:00AM	Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Nov-03-25 10:00AM	Earnings Preview: Arcturus Therapeutics (ARCT) Q3 Earnings Expected to Decline (Zacks) -6.72%
Oct-28-25 04:01PM	Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025 (Business Wire) -6.70%
08:15AM	NeoGenomics (NEO) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
Oct-24-25 09:34AM	Coinbase, eBay upgraded: Wall Street's top analyst calls (The Fly) -6.50%
Oct-23-25 09:39AM	LendingClub upgraded, Enphase Energy downgraded: Wall Street's top analyst calls (The Fly)
09:15AM	Cathie Wood Goes Shopping: 3 Stocks She Just Bought (Motley Fool)
Oct-22-25 04:09PM	Arcturus Crashes 50% On 'Underwhelming' Results For mRNA-Tied Cystic Fibrosis Drug (Investor's Business Daily) -50.17%
08:50AM	Zacks.com featured highlights include Flux Power, Aura Minerals, Arcturus Therapeutics and Sterling Infrastructure (Zacks)
05:57AM	Arcturus Therapeutics (ARCT) Moves 7.7% Higher: Will This Strength Last? (Zacks)
Oct-21-25 09:07AM	4 Stocks With Recent Price Strength to Maximize Your Gains (Zacks) +7.67%
Oct-15-25 09:40AM	Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year? (Zacks)
08:50AM	Arcturus Therapeutics (ARCT) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Oct-03-25 09:51AM	Recursion Pharmaceuticals (RXRX) Surges 8.2%: Is This an Indication of Further Gains? (Zacks)
Sep-19-25 08:31AM	Cathie Wood Snaps Up $49 Million in This Little-Known Sports Company (GuruFocus.com)
06:50AM	Arcturus Therapeutics (ARCT) Surges 8.7%: Is This an Indication of Further Gains? (Zacks)
Sep-15-25 08:30AM	Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth (PR Newswire)
Sep-01-25 09:55AM	Should You Buy Arcturus Therapeutics (ARCT) After Golden Cross? (Zacks)
Aug-26-25 04:01PM	Arcturus Therapeutics to Attend Upcoming Investor Conferences (Business Wire)
Aug-11-25 06:55PM	Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +30.73%
05:53PM	Arcturus Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress (Business Wire)
Aug-08-25 05:30PM	Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
09:26AM	What To Expect From Arcturus Therapeutics Holdings Inc (ARCT) Q2 2025 Earnings (GuruFocus.com)
Aug-07-25 08:20AM	Insmed (INSM) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Aug-05-25 08:15AM	Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Jul-24-25 04:01PM	Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025 (Business Wire)
Jul-23-25 04:01PM	Arcturus Therapeutics to Attend Upcoming Investor Conferences (Business Wire) +6.33%
Jun-30-25 11:00AM	Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program (Business Wire)
Jun-23-25 08:30AM	Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency (Business Wire)
Jun-03-25 09:55AM	Wall Street Analysts Think Arcturus Therapeutics (ARCT) Could Surge 371.35%: Read This Before Placing a Bet (Zacks)
May-29-25 04:01PM	Arcturus Therapeutics to Attend Upcoming Investor Conferences (Business Wire) +7.70%
May-15-25 09:55AM	Wall Street Analysts Believe Arcturus Therapeutics (ARCT) Could Rally 503.6%: Here's is How to Trade (Zacks) +7.38%
May-13-25 08:44AM	Q1 2025 Arcturus Therapeutics Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
03:10AM	Arcturus Therapeutics Holdings Inc (ARCT) Q1 2025 Earnings Call Highlights: Strategic Focus and ... (GuruFocus.com)
May-12-25 05:10PM	Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +5.56%
04:08PM	Arcturus Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress (Business Wire)
May-09-25 09:39AM	Earnings To Watch: Arcturus Therapeutics Holdings Inc (ARCT) Reports Q1 2025 Result (GuruFocus.com)
May-05-25 10:00AM	Earnings Preview: Arcturus Therapeutics (ARCT) Q1 Earnings Expected to Decline (Zacks) -7.09%
Apr-22-25 04:01PM	Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025 (Business Wire) +10.64%
Apr-11-25 11:49AM	Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate (Zacks)
Apr-10-25 08:00AM	Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1 (Business Wire)
Mar-20-25 04:36PM	Is Arcturus Therapeutics (ARCT) a Worst High-Risk High-Reward Growth Stock to Buy? (InsiderMonkey)
Mar-07-25 11:16AM	Q4 2024 Arcturus Therapeutics Holdings Inc Earnings Call (Thomson Reuters StreetEvents) -8.89%
02:17AM	Arcturus Therapeutics Holdings Inc (ARCT) Q4 2024 Earnings Call Highlights: Navigating ... (GuruFocus.com)
Mar-06-25 05:15PM	Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:26PM	Arcturus Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress (Business Wire)
Mar-05-25 04:30PM	Arcturus Therapeutics to Present at Leerinks Global Healthcare Conference 2025 (Business Wire)
07:21AM	Arcturus Therapeutics Holdings Inc (ARCT) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-24-25 04:01PM	Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025 (Business Wire) -6.08%
Feb-14-25 08:30AM	European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE, the First Self-amplifying mRNA COVID-19 Vaccine (PR Newswire) +9.99%
Feb-04-25 08:30AM	Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate (Business Wire)
Jan-31-25 03:00AM	Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE, a Self-amplifying mRNA Vaccine Against COVID-19 (Business Wire)
Jan-30-25 04:01PM	Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference (Business Wire)
Jan-10-25 11:14AM	Arcturus Therapeutics launches Phase I Avian Influenza trials in US (Clinical Trials Arena) -5.12%

Show Previous News

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

FounderMr. Joseph E. Payne M.Sc.

FounderDr. Padmanabh Chivukula Ph.D.

Principal Accounting Officer & ControllerMr. Joseph Roberts

Chief Legal OfficerMr. Lance Kurata

Chief Financial OfficerMr. Dennis M. Mulroy

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARCT

Arcturus Therapeutics Holdings Inc

Upgrade your Finviz experience